RxDoctor Payments Data

James Wiaduck, MD

Psychiatry · Norton Shores, MINPI 1114946506

Payments from drug & device makers

$6,474in general payments, 2019–2025

Across 177 payments — averaging $36.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$973
  • Teva Pharmaceuticals USA, Inc.$956
  • Johnson & Johnson$681
  • AbbVie$454
  • Lundbeck LLC$454
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,461100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,474 in reported general payments places this provider in the 90th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$37,214
Medicare patients
42
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$104,432
VraylarCariprazine Hcl27$54,054
Aripiprazole62$9,978
Adderall XrDextroamphetamine/Amphetamine11$9,323
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$5,495
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine143$4,888
Rivastigmine12$4,225
Methylphenidate Er (La)Methylphenidate Hcl17$4,062
Methylphenidate ErMethylphenidate Hcl12$4,015
Trazodone Hcl91$3,997
Buprenorphine Hcl89$3,258
Quetiapine Fumarate67$2,976
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$2,870
Lamotrigine78$2,550
Lisdexamfetamine Dimesylate11$2,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,220$104,43213 claims
AbbVieVraylar$454$54,05427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →